Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 19, 2021 12:07pm
131 Views
Post# 32326696

RE:RE:New investors from the deal

RE:RE:New investors from the dealWhatever makes the most sense from a funding standpoint but I was thinking half a warrant for each share owned just like the new shareholders got. That would raise about $122 million if fully exercised in addition to the $27 million additional funds coming in from the warrants from the deal. 

Obviously the terms could be adjusted (for example a lower exercise price) of the company does not want to raise quite that mich money but my guess is there is a good chance they will need it. 

Now, there are no doubt all sorts of problems with this idea from a regulatory perspective. But if they can be worked around, and usually they can, why not do it? 

JayjayUSA12007 wrote:
SPCEO: "I have an idea for the company to consider. It would seem fait to me if the company granted outright to all current shareholders the same warrant they just sold to the new investors."

That would be a good idea and fair. After all, Thera still needs more money to further its clinical trials.
Would the number of warrants granted to existing shareholders be proportional to their current holdings ?


<< Previous
Bullboard Posts
Next >>